← All trials
NCT05211232
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 25, 2022
- Primary completion
- Mar 25, 2024
- Completion date
- Mar 25, 2027
- First posted
- Jan 27, 2022
- Last posted
- Mar 4, 2022
- Enrollment
- 450
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Central South UniversityCollaborator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityReponsible party - principal investigator
- Wuzhou Red Cross HospitalCollaborator
- Guizhou Medical UniversityCollaborator
- Guangdong Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.